bearish
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap
603 Views11 Sep 2019 14:19
Shanghai Henlius, a biotech subsidiary of Fosun Pharma, launched book building today to raise up to USD 477 million.
In our previous insights...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
- Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China18 Sep 2019
- ECM Weekly (14 Sep 2019) - Budweiser APAC, ESR Cayman, Henlius, AllHome, Topsports14 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization13 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap11 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation22 Aug 2019
- Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?17 Jul 2019
x